Literature DB >> 28956200

Magnetic resonance guided renal denervation using active tracking: first in vivo experience in Swine.

F Bönner1, S Haberkorn1, P Behm1, B Schnackenburg2, S Krüger2, S Weiss2, C Meyer1,3, M Kelm1,4, M Neizel-Wittke5.   

Abstract

Interventional cardiovascular magnetic resonance (iCMR) might evolve as a technique to improve procedural success rates in cardiovascular interventions by combining intraprocedural guidance and simultaneous lesion imaging. The objective of the present study was to prove feasibility and estimate safety of renal sympathetic denervation guided by real-time iCMR using active tracking. Six pigs were examined in a 1.5 T MRI-System (Achieva, Philips Healthcare, Best, Netherlands) equipped with non-invasive hemodynamic control and in-room monitors displaying an interventional software platform [Interventional MRI Suite (iSuite), Philips Research, Hamburg, Germany]. MR-guided renal denervation was performed using a MR conditional non-irrigated ablation catheter with active tracking (Imricor, Burnsville, MN, USA). Real-time imaging for device guidance was performed with a TFE sequence, vessel patency was assessed with a 3D non-contrast angiography and velocity encoded imaging. Oedema of the renal artery was visualized by a high-resolution T2 SPIR sequence. Renal sympathetic denervation was feasible in all cases with survival of all animals. Non-contrast angiography displayed renal artery patency accompanied by equal flow conditions before and after the ablation in all cases as measured by velocity encoded imaging. Oedema imaging displayed a significant increase in relative signal intensity at renal artery ablations sites pre and post intervention (p < 0.05). The histologic examination revealed no signs of perforation or bleeding, while sufficient ablation lesions could be depicted. MR-guided renal sympathetic denervation using active tracking is feasible and the initial data suggest safety of this procedure. MR-guided renal sympathetic denervation offers the inherent strength of high soft tissue contrast thereby providing target information without the use of iodinated contrast agents or radiation.

Entities:  

Keywords:  Arterial hypertension; Interventional MRI; Renal denervation

Mesh:

Year:  2017        PMID: 28956200     DOI: 10.1007/s10554-017-1244-6

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  21 in total

1.  The effects of splanchnicectomy on the blood pressure in hypertension; a controlled study.

Authors:  S W HOOBLER; J T MANNING; W G PAINE; S G McCLELLAN; P O HELCHER; H RENFERT; M M PEET; E A KAHN
Journal:  Circulation       Date:  1951-08       Impact factor: 29.690

2.  Comparison of renal artery, soft tissue, and nerve damage after irrigated versus nonirrigated radiofrequency ablation.

Authors:  Kenichi Sakakura; Elena Ladich; Kristine Fuimaono; Debby Grunewald; Patrick O'Fallon; Anna-Maria Spognardi; Peter Markham; Fumiyuki Otsuka; Kazuyuki Yahagi; Kai Shen; Frank D Kolodgie; Michael Joner; Renu Virmani
Journal:  Circ Cardiovasc Interv       Date:  2014-12-31       Impact factor: 6.546

3.  Magnetic resonance imaging guided transatrial electrophysiological studies in swine using active catheter tracking - experience with 14 cases.

Authors:  Matthias Grothoff; Matthias Gutberlet; Gerhard Hindricks; Christian Fleiter; Bernhard Schnackenburg; Steffen Weiss; Sascha Krueger; Christopher Piorkowski; Thomas Gaspar; Steve Wedan; Thomas Lloyd; Philipp Sommer; Sebastian Hilbert
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

4.  Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.

Authors:  Dharam J Kumbhani; P Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Kevin Crowley; Shinya Goto; E Magnus Ohman; George L Bakris; Todd S Perlstein; Scott Kinlay; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2012-11-09       Impact factor: 29.983

Review 5.  Resistant hypertension--its identification and epidemiology.

Authors:  Pantelis A Sarafidis; Panagiotis Georgianos; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

Review 6.  The sympathetic system and hypertension.

Authors:  M Esler
Journal:  Am J Hypertens       Date:  2000-06       Impact factor: 2.689

Review 7.  Worldwide prevalence of hypertension: a systematic review.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul K Whelton; Jiang He
Journal:  J Hypertens       Date:  2004-01       Impact factor: 4.844

8.  Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model.

Authors:  Tim A Fischell; Felix Vega; Narayan Raju; Eric T Johnson; Darrin J Kent; Robert R Ragland; David R Fischell; Steven L Almany; Vartan E Ghazarossian
Journal:  EuroIntervention       Date:  2013-05-20       Impact factor: 6.534

9.  Myocardial T2 mapping reveals age- and sex-related differences in volunteers.

Authors:  Florian Bönner; Niko Janzarik; Christoph Jacoby; Maximilian Spieker; Bernhard Schnackenburg; Felix Range; Britta Butzbach; Sebastian Haberkorn; Ralf Westenfeld; Mirja Neizel-Wittke; Ulrich Flögel; Malte Kelm
Journal:  J Cardiovasc Magn Reson       Date:  2015-02-06       Impact factor: 5.364

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

View more
  1 in total

1.  CMR-guidance of passively tracked endomyocardial biopsy in an in vivo porcine model.

Authors:  P Behm; M Gastl; A Jahn; A Rohde; S Haberkorn; S Krueger; S Weiss; B Schnackenburg; M Sager; K Düring; H Clogenson; P Horn; R Westenfeld; M Kelm; M Neizel-Wittke; F Bönner
Journal:  Int J Cardiovasc Imaging       Date:  2018-06-19       Impact factor: 2.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.